Dr. Angelo Pirozzi from Mayo Clinic in conversation with Dr. Rutika Mehta from NewYork-Presbyterian Hospital
Dr. Mehta elaborated on the significance of this new therapy, Zolbetuximab, its mechanism of action, and the results from the pivotal GLOW and SPOTLIGHT trials that led to its approval. The discussion also touched on the overlap of Claudin 18.2 with other biomarkers like HER2 and PD-L1, as well as the challenges and side effects associated with the treatment, including nausea and vomiting.
